Proactive Investors - Run By Investors For Investors

Wayland soars as it finalizes international asset, license portfolio deal with ICC International Cannabis

As part of the deal, Wayland will ink a three-year supply agreement with ICC to supply it with 10,000 kilograms annually of dried cannabis flower from its Ontario facility
cannabis leaf
The two companies expect the deal to drive revenue higher as they look to take advantage of economies of scale to improve production, distribution and branding

Shares of Wayland Group Corp (OTCMKTS:MRRCF) (CSE:WAYL) climbed Friday, as ICC International Cannabis Corp (CSE:WRLD.U) (OTCMKTS:WLDCF) announced it closed its previously announced acquisition of 49.9% of Wayland’s international asset and license portfolio.

As part of the deal, Wayland will enter into a three-year supply agreement with ICC to supply it with 10,000 kg annually of dried cannabis flower grown at Wayland’s Langton, Ontario production facility.

Shares of Wayland Group soared 6.2% at US$0.69 by Friday's close in New York.

READ: ICC International Cannabis strikes definitive agreement to acquire 49.9% of Wayland Group's International Asset and Licence portfolio

The cannabis will be distributed across medical cannabis markets in Europe and is expected to pay ICC more than eight euros per gram.

Under the deal, International Cannabis will issue Wayland 300 million shares in the capital of ICC.

The two companies expect the deal will drive revenue higher as they look to take advantage of economies of scale to improve production, distribution and branding campaigns and enter new cannabis and CBD markets.

Shares of ICC International Cannabis Corp were at US$0.20 on Friday. 

Contact Katie Lewis at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full WAYL profile View Profile

Wayland Group Inc Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use